000			01966 a2200553 4500
005			20250514221759.0
264		0	_c20050818
008			200508s 0 0 eng d
022			_a0268-3369
024	7		_a10.1038/sj.bmt.1704887 _2doi
040			_aNLM _beng _cNLM
100	1		_aLoren, A W
245	0	0	_aIntensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation. _h[electronic resource]
260			_bBone marrow transplantation _cMay 2005
300			_a921-6 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAlemtuzumab
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibodies, Neoplasm _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aGraft vs Host Disease _xcomplications
650	0	4	_aHematopoietic Stem Cell Transplantation
650	0	4	_aHumans
650	0	4	_aLymphoproliferative Disorders _xcomplications
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMycophenolic Acid _xadministration & dosage
650	0	4	_aTransplantation Chimera
650	0	4	_aTransplantation Conditioning _xmethods
650	0	4	_aVidarabine _xadministration & dosage
700	1		_aLuger, S M
700	1		_aStadtmauer, E A
700	1		_aTsai, D E
700	1		_aSchuster, S
700	1		_aNasta, S D
700	1		_aGoldstein, S C
700	1		_aPerl, A
700	1		_aOrloff, G
700	1		_aOliver, J C
700	1		_aGreen, J
700	1		_aEmerson, S G
700	1		_aPorter, D L
773	0		_tBone marrow transplantation _gvol. 35 _gno. 9 _gp. 921-6
856	4	0	_uhttps://doi.org/10.1038/sj.bmt.1704887 _zAvailable from publisher's website
999			_c15437933 _d15437933